NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer - PubMed (original) (raw)
NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer
Thomas W Flaig. J Natl Compr Canc Netw. 2019.
Abstract
The treatment landscape of bladder cancer has changed rapidly over the past several years. The 2019 version of the NCCN Guidelines has integrated changes to tumor staging that reflect an updated understanding of the natural history of the disease and will affect how patients are treated. Further, 5 PD-1/PD-L1 immune checkpoint inhibitors (ICIs) are approved for the treatment of bladder cancer. The FDA has limited use of ICIs as monotherapy in the first-line treatment of metastatic and advanced disease for patients who are platinum-ineligible or are cisplatin-ineligible with high PD-L1 expression and are candidates for ICIs. Ongoing predictive biomarker development and validation are needed in bladder cancer; the development of better biomarkers will be key in patient selections for therapy going forward.
Similar articles
- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Spiess PE, et al. J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156. J Natl Compr Canc Netw. 2017. PMID: 28982750 - Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M, Roumiguié M, Houédé N, Masson-Lecomte A, Colin P, Pignot G, Larré S, Xylinas E, Rouprêt M, Neuzillet Y. Rouanne M, et al. World J Urol. 2018 Nov;36(11):1727-1740. doi: 10.1007/s00345-018-2332-5. Epub 2018 Jun 1. World J Urol. 2018. PMID: 29855698 Review. - NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. Flaig TW, et al. J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072. J Natl Compr Canc Netw. 2018. PMID: 30181416 - SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).
González Del Alba A, De Velasco G, Lainez N, Maroto P, Morales-Barrera R, Muñoz-Langa J, Pérez-Valderrama B, Basterretxea L, Caballero C, Vazquez S. González Del Alba A, et al. Clin Transl Oncol. 2019 Jan;21(1):64-74. doi: 10.1007/s12094-018-02001-x. Epub 2018 Dec 18. Clin Transl Oncol. 2019. PMID: 30565086 Free PMC article. - Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ, Sonpavde G. Einstein DJ, et al. Curr Treat Options Oncol. 2019 Feb 11;20(2):12. doi: 10.1007/s11864-019-0609-6. Curr Treat Options Oncol. 2019. PMID: 30741358 Review.
Cited by
- A comparative study of survival outcomes between partial and radical cystectomy in octogenarians with muscle-invasive bladder cancer.
Pon Avudaiappan A, Prabhakar P, Lusnia C, Ganiyani MA, Rubens M, Garje R, Eldefrawy A, Manoharan M. Pon Avudaiappan A, et al. Transl Androl Urol. 2024 Aug 31;13(8):1486-1497. doi: 10.21037/tau-24-139. Epub 2024 Aug 16. Transl Androl Urol. 2024. PMID: 39280660 Free PMC article. - MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy.
Zhang X, Wang Y, Wang Y, Zhang J, Zhang J, Zhang L, Wang S, Shou J, Chen Y, Zhao X. Zhang X, et al. Cancer Imaging. 2024 Apr 8;24(1):49. doi: 10.1186/s40644-024-00696-6. Cancer Imaging. 2024. PMID: 38584289 Free PMC article. - Early port site and peritoneal metastasis following robot-assisted radical cystectomy: a rare case report.
Tripathi S, Bhirud DP, Singh M, Singh V, Choudhary GR, Navriya S, Jena R, Sandhu AS. Tripathi S, et al. J Cancer Res Clin Oncol. 2024 Jan 25;150(2):32. doi: 10.1007/s00432-023-05562-9. J Cancer Res Clin Oncol. 2024. PMID: 38270652 Free PMC article. - The prognosis and safety of continuous saline bladder irrigation in patients after transurethral resection of bladder tumors: a systematic review and meta-analysis of comparative study.
Wang X, Wang Y, Che X, Zhou Z, Cheng B. Wang X, et al. Updates Surg. 2023 Oct;75(7):1795-1806. doi: 10.1007/s13304-023-01525-4. Epub 2023 May 15. Updates Surg. 2023. PMID: 37188906 Review. - Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma.
Drobner JC, Lichtbroun BJ, Singer EA, Ghodoussipour S. Drobner JC, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231164196. doi: 10.1177/15330338231164196. Technol Cancer Res Treat. 2023. PMID: 36938621 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous